These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 32888052)

  • 1. Doctor's aptitude for switching from innovator etanercept to biosimilar etanercept in inflammatory rheumatic diseases: experience from a single French rheumatology tertiary care center.
    Al Tabaa O; Etcheto A; Dumas S; Batteux F; Goulvestre C; Moltó A; Miceli-Richard C; Dougados M
    Eur J Clin Pharmacol; 2021 Jan; 77(1):25-33. PubMed ID: 32888052
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acceptance rate and sociological factors involved in the switch from originator to biosimilar etanercept (SB4).
    Scherlinger M; Langlois E; Germain V; Schaeverbeke T
    Semin Arthritis Rheum; 2019 Apr; 48(5):927-932. PubMed ID: 30093238
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Switch from reference etanercept to SDZ ETN, an etanercept biosimilar, does not impact efficacy, safety, and immunogenicity of etanercept in patients with moderate-to-severe rheumatoid arthritis: 48-week results from the phase III, randomized, double-blind EQUIRA study.
    Jaworski J; Matucci-Cerinic M; Schulze-Koops H; Buch MH; Kucharz EJ; Allanore Y; Kavanaugh A; Young P; Babic G
    Arthritis Res Ther; 2019 May; 21(1):130. PubMed ID: 31138316
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systematic switch from innovator infliximab to biosimilar infliximab in inflammatory chronic diseases in daily clinical practice: The experience of Cochin University Hospital, Paris, France.
    Avouac J; Moltó A; Abitbol V; Etcheto A; Salcion A; Gutermann L; Klotz C; Elhai M; Cohen P; Soret PA; Morin F; Conort O; Chast F; Goulvestre C; Jeunne CL; Chaussade S; Kahan A; Roux C; Allanore Y; Dougados M
    Semin Arthritis Rheum; 2018 Apr; 47(5):741-748. PubMed ID: 29102156
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment retention of infliximab and etanercept originators versus their corresponding biosimilars: Nordic collaborative observational study of 2334 biologics naïve patients with spondyloarthritis.
    Lindström U; Glintborg B; Di Giuseppe D; Nordström D; Aarrestad Provan S; Gudbjornsson B; Askling J; Lund Hetland M; Aaltonen K; Krogh NS; Geirsson AJ; Jacobsson LTH
    RMD Open; 2019; 5(2):e001079. PubMed ID: 31749988
    [TBL] [Abstract][Full Text] [Related]  

  • 6. To switch or not to switch: results of a nationwide guideline of mandatory switching from originator to biosimilar etanercept. One-year treatment outcomes in 2061 patients with inflammatory arthritis from the DANBIO registry.
    Glintborg B; Loft AG; Omerovic E; Hendricks O; Linauskas A; Espesen J; Danebod K; Jensen DV; Nordin H; Dalgaard EB; Chrysidis S; Kristensen S; Raun JL; Lindegaard H; Manilo N; Jakobsen SH; Hansen IMJ; Dalsgaard Pedersen D; Sørensen IJ; Andersen LS; Grydehøj J; Mehnert F; Krogh NS; Hetland ML
    Ann Rheum Dis; 2019 Feb; 78(2):192-200. PubMed ID: 30396903
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term efficacy, safety and immunogenicity in patients with rheumatoid arthritis continuing on an etanercept biosimilar (LBEC0101) or switching from reference etanercept to LBEC0101: an open-label extension of a phase III multicentre, randomised, double-blind, parallel-group study.
    Park MC; Matsuno H; Kim J; Park SH; Lee SH; Park YB; Lee YJ; Lee SI; Park W; Sheen DH; Choe JY; Choi CB; Hong SJ; Suh CH; Lee SS; Cha HS; Yoo B; Hur JW; Kim GT; Yoo WH; Baek HJ; Shin K; Shim SC; Yang HI; Kim HA; Park KS; Choi IA; Lee J; Tomomitsu M; Shin S; Lee J; Song YW
    Arthritis Res Ther; 2019 May; 21(1):122. PubMed ID: 31113455
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy.
    Emery P; Vencovský J; Sylwestrzak A; Leszczyński P; Porawska W; Baranauskaite A; Tseluyko V; Zhdan VM; Stasiuk B; Milasiene R; Barrera Rodriguez AA; Cheong SY; Ghil J
    Ann Rheum Dis; 2017 Jan; 76(1):51-57. PubMed ID: 26150601
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Post-switch Effectiveness of Etanercept Biosimilar Versus Continued Etanercept in Rheumatoid Arthritis Patients with Stable Disease: A Prospective Multinational Observational Study.
    Pope J; Hall S; Bombardier C; Haraoui B; Jones G; Naik L; Etzel CJ; Ramey DR; Infante R; Miguelez M; Falcao S; Sahakian S; Wu D
    Adv Ther; 2022 Nov; 39(11):5259-5273. PubMed ID: 36136243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase III, multicentre, randomised, double-blind, active-controlled, parallel-group trial comparing safety and efficacy of HD203, with innovator etanercept, in combination with methotrexate, in patients with rheumatoid arthritis: the HERA study.
    Bae SC; Kim J; Choe JY; Park W; Lee SH; Park YB; Shim SC; Lee SS; Sung YK; Choi CB; Lee SR; Park H; Ahn Y;
    Ann Rheum Dis; 2017 Jan; 76(1):65-71. PubMed ID: 26905864
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Costs associated with non-medical switching from originator to biosimilar etanercept in patients with rheumatoid arthritis in the UK.
    Tarallo M; Onishchenko K; Alexopoulos ST
    J Med Econ; 2019 Nov; 22(11):1162-1170. PubMed ID: 31373527
    [No Abstract]   [Full Text] [Related]  

  • 12. Efficacy and safety of a single switch from etanercept originator to etanercept biosimilar in a cohort of inflammatory arthritis.
    Ditto MC; Parisi S; Priora M; Sanna S; Peroni CL; Laganà A; D'Avolio A; Fusaro E
    Sci Rep; 2020 Sep; 10(1):16178. PubMed ID: 32999362
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy, immunogenicity and cost analysis of a systematic switch from originator infliximab to biosimilar CT-P13 of all patients with inflammatory arthritis from a single center.
    Valido A; Silva-Dinis J; Saavedra MJ; Iria I; Gonçalves J; Lopes JP; Fonseca JE
    Acta Reumatol Port; 2019; 44(4):303-311. PubMed ID: 31754088
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does a mandatory non-medical switch from originator to biosimilar etanercept lead to increase in healthcare use and costs? A Danish register-based study of patients with inflammatory arthritis.
    Glintborg B; Ibsen R; Bilbo REQ; Lund Hetland M; Kjellberg J
    RMD Open; 2019; 5(2):e001016. PubMed ID: 31452931
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Open-Label, Non-Mandatory Transitioning From Originator Etanercept to Biosimilar SB4: Six-Month Results From a Controlled Cohort Study.
    Tweehuysen L; Huiskes VJB; van den Bemt BJF; Vriezekolk JE; Teerenstra S; van den Hoogen FHJ; van den Ende CH; den Broeder AA
    Arthritis Rheumatol; 2018 Sep; 70(9):1408-1418. PubMed ID: 29609207
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative effectiveness of etanercept originator and biosimilar for treating rheumatoid arthritis: implications for cost-savings.
    Deakin CT; Littlejohn GO; Griffiths H; Ciciriello S; O'Sullivan C; Smith T; Youssef P; Bird P;
    Intern Med J; 2024 May; 54(5):795-801. PubMed ID: 38009675
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of safety and effectiveness between etanercept biosimilar LBEC0101 and reference in patients with rheumatoid arthritis in real-world data using the KURAMA cohort.
    Kawakami T; Masui S; Onishi A; Onizawa H; Fujii T; Murakami K; Murata K; Tanaka M; Shimada T; Nakagawa S; Matsuda S; Morinobu A; Terada T; Yonezawa A
    Mod Rheumatol; 2024 Oct; 34(6):1135-1141. PubMed ID: 38516944
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of switching from originator etanercept to biosimilar YLB113 in real-world patients with rheumatoid arthritis: A retrospective 12 months follow-up study.
    Sakane H; Yonemoto Y; Okamura K; Suto T; Inoue M; Mitomi H; Tsuchida K; Kaneko T; Tamura Y; Chikuda H
    J Orthop Surg (Hong Kong); 2024; 32(2):10225536241265818. PubMed ID: 38907590
    [No Abstract]   [Full Text] [Related]  

  • 19. 52-week results of the phase 3 randomized study comparing SB4 with reference etanercept in patients with active rheumatoid arthritis.
    Emery P; Vencovský J; Sylwestrzak A; Leszczynski P; Porawska W; Baranauskaite A; Tseluyko V; Zhdan VM; Stasiuk B; Milasiene R; Barrera Rodriguez AA; Cheong SY; Ghil J
    Rheumatology (Oxford); 2017 Dec; 56(12):2093-2101. PubMed ID: 28968793
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcomes following switching from etanercept originator to etanercept biosimilar in 1024 patients with RA: a matched-analysis of the BSRBR-RA.
    Kearsley-Fleet L; Rokad A; Tsoi MF; Zhao SS; Lunt M; Watson KD; ; Hyrich KL
    Rheumatology (Oxford); 2024 Aug; 63(8):2082-2092. PubMed ID: 37672014
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.